Developer site: The content shown here is test data.

Health Dictionary AI Health Chat Find an Online Doctor
A serene Zen garden with raked sand and smooth stones, symbolising clarity and calm

Health Dictionary

Back to skin conditions

Seminoma natural history, complications and prognosis

Introduction

Overview

Overview

Common complications of seminoma include recurrence, lymph node metastasis, distant metastasis, and secondary malignancies. Prognosis is generally good for all stages with greater than 90% cure rate. Seminoma grows slower than non-seminomatous germ cell tumors. The International Germ Cell Cancer Consensus Group divides seminoma into two prognosis groups: good and intermediate. The symptoms of seminoma usually develop in the second to forth decade of life (15-35 years), and start with symptoms such as a painless testicular lump, abnormal semen analysis, possibly an acute onset testicular pain.

Natural History

Natural History

Complications

Complications

Common complications of seminoma include:[2]

Prognosis

Prognosis

  • Prognosis for stage I is excellent, and the survival rate of patients with seminoma for satgr I is approximately 100%.[3][4]
  • Prognosis for stage II is generally good, the 5-year mortality survival rate of patients with satge II of seminoma is approximately 97%.
  • Prognosis for stage III is generally good, the 5-year mortality survival rate of patients with satge III of seminoma is approximately 85%.
References

References

  1. ↑ Boujelbene N, Cosinschi A, Boujelbene N, Khanfir K, Bhagwati S, Herrmann E, Mirimanoff RO, Ozsahin M, Zouhair A (August 2011). “Pure seminoma: a review and update”. Radiat Oncol. 6: 90. doi:10.1186/1748-717X-6-90. PMC 3163197. PMID 21819630.
  2. ↑ Testicular seminoma. Dr Marcin Czarniecki and Dr Andrew Dixon et al. Radiopaedia 2016. http://radiopaedia.org/articles/testicular-seminoma-1. Accessed on March 3, 2016
  3. ↑ Dong W, Gang W, Liu M, Zhang H (February 2016). “Analysis of the prognosis of patients with testicular seminoma”. Oncol Lett. 11 (2): 1361–1366. doi:10.3892/ol.2015.4065. PMC 4734256. PMID 26893743.
  4. ↑ Honecker, F; Aparicio, J; Berney, D; Beyer, J; Bokemeyer, C; Cathomas, R; Clarke, N; Cohn-Cedermark, G; Daugaard, G; Dieckmann, K -P; Fizazi, K; FossÃ¥, S; Germa-Lluch, J R; Giannatempo, P; Gietema, J A; Gillessen, S; Haugnes, H S; Heidenreich, A; Hemminki, K; Huddart, R; Jewett, M A S; Joly, F; Lauritsen, J; Lorch, A; Necchi, A; Nicolai, N; Oing, C; Oldenburg, J; OndruÅ¡, D; Papachristofilou, A; Powles, T; Sohaib, A; StÃ¥hl, O; Tandstad, T; Toner, G; Horwich, A (2018). “ESMO Consensus Conference on testicular germ cell cancer: diagnosis, treatment and follow-up”. Annals of Oncology. 29 (8): 1658–1686. doi:10.1093/annonc/mdy217. ISSN 0923-7534.

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Sogand Goudarzi, MD [2]